Berggren R E, Wunderlich A, Ziegler E, Schleicher M, Duke R C, Looney D, Fang F C
Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver 80267, USA.
J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Dec 15;10(5):489-95.
Salmonella is of great interest as a potential human immunodeficiency virus vaccine vector because of its ability to elicit potent mucosal and systemic immune responses when administered orally. To determine whether such a vaccine could elicit an immune response in mice, plasmids expressing HIV gp120-LAI were introduced into attenuated S. typhimurium. Three serial doses of 10(10) recombinant organisms were administered orally to BALB/c mice at 2-week intervals. Immunized mice but not control mice demonstrated proliferative T cell responses to gp120-LAI, comparable in magnitude to the proliferative responses to Salmonella antigens. Immunized mice had detectable serum and intestinal Salmonella-specific IgA and serum Salmonella-specific IgG. However, no gp120-specific antibody was detected in either serum or intestinal washes. These results indicate that live recombinant Salmonella-based vaccine constructs can induce HIV-specific cellular immune responses in vivo.
沙门氏菌作为一种潜在的人类免疫缺陷病毒疫苗载体备受关注，因为口服给药时它能够引发强烈的黏膜和全身免疫反应。为了确定这种疫苗是否能在小鼠体内引发免疫反应，将表达HIV gp120-LAI的质粒导入减毒鼠伤寒沙门氏菌中。以2周的间隔向BALB/c小鼠口服给予三剂连续剂量的10(10)重组菌。免疫小鼠而非对照小鼠表现出对gp120-LAI的增殖性T细胞反应，其强度与对沙门氏菌抗原的增殖反应相当。免疫小鼠的血清和肠道中可检测到沙门氏菌特异性IgA以及血清沙门氏菌特异性IgG。然而，在血清或肠道冲洗液中均未检测到gp120特异性抗体。这些结果表明，基于活重组沙门氏菌的疫苗构建体能够在体内诱导HIV特异性细胞免疫反应。
